Abstract: A method of monitoring and evaluating the dry-blending of powders and granular materials via the use of non-dissolvable particulate matter such as mustard seed as a blending aid. The mustard seed is blended into the total batch of dry blend materials and the mustard seed can subsequently be extracted by a process of sieving from a known volume of sample taken of the mixture since the mustard seed is larger than the other particles that are being blended. The weight and or sight count of the extracted mustard seed present in the sample is determined and compared with the amount of seed that should be present in a perfect blend to determine if the dry blend materials are thoroughly mixed.

Abstract: A two step process for treating an oil or gas well. The first step uses a cross linking agent, such as borax, as a preliminary wash for the well following drilling. The cross linking agent cleans the well of excess mud and pre-coats the tubing and the formation surfaces with the cross linking agent. The second step introduces a cement-polymer mixture into the well. A polymer, such as for example polyvinyl alcohol, that undergoes cross linking when exposed to the cross linking agent is employed. When the polymer comes into contact with the cross linking agent in the well, cross linking of the polymer occurs. This cross linking helps to prevent fluid loss into the formation. Also, because the cross linking agent wash previously cleaned the surfaces of the tubing and the formation, better bonding between the cement and the surfaces of the tubing and the formation occurs.

Abstract: There is provided a polymer having a side chain of general formula (I) in which R may be any suitable alkyl, oxyalkyl, aryl or oxyaryl linking group R is preferably C1-6 alkyl (especially —CH2—), a benzene group or a group —CH2—O-Phe-. Generally, the side chain will be attached to an ethylene moiety forming part of the backbone of the polymer. Preferred polymers include polystyrene. The polymer is useful as a support for solid phase chemical reactions especially combinatorial chemical synthesis.

Abstract: The invention relates to a system for administering muscle relaxant to a patient. The system includes an infusion pump adapted for delivering said muscle relaxant to a patient, and a controller adapted for controlling the operation of said infusion pump on the basis of at least one received input value. Further the system includes measuring means adapted for continuously measuring the effect of said muscle relaxant on the patient and adapted for supplying a value representing said measured effect as said input value to said controller. According to the invention, on basis of said at least one input value, said controller is adapted for selecting a control value from a set of predetermined control values as the value to be used for controlling said infusion pump. The invention also relates to a method of administering muscle relaxant to a patient and to a testing apparatus adapted to be used for testing the automatic operation of a system for administration of muscle relaxant to a patient.

Abstract: The invention provides an equine infectious anemia (EIA) vaccine that provides immunity to mammals, especially equines, from infection with equine infectious anemia virus (EIAV) and which allows differentiation between vaccinated and non-vaccinated, but exposed, mammals or equines. Preferably said vaccine encompasses at least one mutation in an EIAV which produces a non-functional gene in the vaccine virus that is always expressed in disease-producing wild-type EIA viruses. Additionally, said EIA vaccine virus cannot cause clinical disease in mammals or spread or shed to other mammals including equines.

Abstract: The present invention relates to a method of treatment of hot flushes with a 5-HT2C receptor agonist and in particular to the use of the selective 5-HT2C receptor agonists 1-[6-chloro-5-(trifluoromethyl)-2-pyridinyl]-piperazine and (S)-(+)-3-[(2,3-dihydro-5-methoxy-1H-inden-4-yl)oxy-pyrrolidine or pharmaceutically acceptable acid addition salts thereof for the manufacture of a pharmaceutical formulation adapted for the treatment of hot flushes.

Abstract: The current invention provides methods for molecule purification by RP-LC and RP-HPLC that uses unbranched terminal alkyldiols as eluting solvents. In particular, the present invention purifies molecules, particularly proteins and peptides, on reverse phase liquid chromatography columns using a buffer containing either 1,5 pentanediol, 1,6 hexanediol or 1,7 heptanediol.

Abstract: Embodiments of the present invention generally relate to novel fed-batch fermentations wherein processes of DO-stat and pH-stat are combined for nutrient feeding control.

Abstract: The present invention provides a new antigenic class of avian reoviruses which are involved in enteric disease conditions in poultry. Moreover, the invention provides a vaccine for use in the protection of poultry against such disease conditions derived from the new type of avian reoviruses.

Abstract: Embodiments of the present invention generally relate to devices and processes related to estrus synchronization. Particular embodiments of devices and processes of the present invention slowly release progesterone over a period of time for estrus synchronization.

Abstract: The present invention describes recombinant RV mutants comprising a combine mutation in two different parts of the viral genome, involving the P and the G genes. The mutations in the P gene preferably encompass residues 139 to 170, more preferably residue 139 to 149, most preferably residues 143-149. The mutation can be a substitution or deletion of one or more amino acids in the above region, as well as combinations of deletion and substitution.

Abstract: The present invention relates to a process for the preparation of peptides using an excess of an activated carboxylic component to acylate an amino component, wherein after the acylation an amine comprising a free anion or a latent anion is used as a scavenger of residual activated carboxylic functions. This process is useful for the preparation of oligo- and polypeptides and, more generally, in the preparation of compounds containing one or more amide bonds.

Abstract: The present invention relates to a process of releasing a protein, recombinant or otherwise, from a cell. The process of the present invention involves contacting a host cell containing a protein of interest with a solution comprising one or more detergents and one or more reducing agents. The methods of the invention are particularly suitable to large scale production of recombinant products.

Abstract: Embodiments of the present invention generally relate to devices and processes related to estrus synchronization. Particular embodiments of devices and processes of the present invention slowly release progesterone over a period of time for estrus synchronization.

Abstract: The present invention relates to vaccines comprising antiserum raised against a flagellaless Campylobacter strain for the prevention of Campylobacter colonization in animals. The invention also relates to antigenic Campylobacter proteins visible in a Western blot of Campylobacter jejuni protein after incubation of said Western blot with antibodies against a flagellaless mutant of Campylobacter jejuni and not visible after incubation of said blot with antibodies against wild type Campylobacter jejuni, and to their use in vaccines and the manufacturing thereof. The invention further relates to vaccines comprising such proteins and antibodies against such proteins. The invention further relates to the use of such Campylobacter proteins and to antiserum and antibodies raised against Campylobacter antigens for the preparation of vaccines. Finally, the invention relates to methods for the preparation of such vaccines.

Abstract: Novel, orally active androgens are 7&agr;-substituted &Dgr;14-nandrolone derivatives. The compounds satisfy the general formula: wherein R1 is O, (H,H), (H,OR), NOR, with R being hydrogen, (C1-6) alkyl, or (C,1-6) acyl; R2 is selected from the group consisting of (C2-4) alkyl, (C2-4) alkenyl, or (C2-4) alkynyl, each optionally substituted by halogen; or R2 is cyclopropyl, or cyclopropenyl, each optionally substituted by (C1-2) alkyl, or halogen; R3 is hydrogen, (C1-2) alkyl, or ethenyl; R4 is (C1-2) alkyl; R5 is hydrogen, or (C1-15) acyl; and the dotted lines indicate optional bonds.

Abstract: The present invention relates to live attenuated RTX-toxin producing bacteria of the family Pasteurellaceae, of which the attenuation is due to the fact that they produce RTX toxin in a non-activated form. The invention also relates to vaccines for the protection of mammals against infection with RTX-toxin producing bacteria of the family Pasteurellaceae, and to methods for the preparation of said live attenuated bacteria and vaccines.

Abstract: Disclosed herein is a multicomponent low dose vaccine comprising a safe and immunogenically effective combination of a protective antigen component or components of clostridial organism, a protective antigen component of a non-clostridial organism and an adjuvant.

Abstract: Disclosed herein is a vaccine which provides immunity to mammals from infection and/or disease caused by a lentivirus, such as equine infectious anemia virus, human immunodeficiency virus (HIV), feline immunodeficiency virus (FIV), bovine immunodeficiency virus (BIV) or simian immunodeficiency virus (SIV) said composition comprising a deletion in a gene that blocks replication of the virus in vivo. Preferably said composition encompasses at least one deletion in a lentivirus which provides protection from exposure to wild-type lentiviruses. It also encompasses a marker vaccine in which a foreign gene is inserted into the gene-deleted region, said inserted gene providing a diagnostic tool for use in vaccinated mammals. The scope of the invention encompasses an EIAV vaccine that allows equines to be safely vaccinated and protected from disease without converting to a seropositive status on the Coggin's Test or any other test wich measures p26.